Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – September 30, 2021…
Month: September 2021
Collaboration with Kissei Pharmaceutical

In 2015, ObsEva entered into a collaboration agreement with Kissei Pharmaceutical Co., Ltd., a Japanese pharmaceutical company with approximately 70…
Collaboration with Organon

In July 2021, Obseva licensed the exclusive worldwide rights to develop, manufacturing and commercial rights to ebopiprant (OBE022) to Organon,…
ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids
-If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of…
HCW Presentation September 13, 2021
ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
GENEVA, Switzerland September 7, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies…